Behandlung von diabetes typ 1 mit hemmern des makrophagen-migrationshemmenden faktorsdoi:EP1740167 A2Methods of treating a mammal having type 1 diabetes or a risk for type 1 diabetes are provided. The methods comprise administering to the mammal a pharmaceutical composition comprising an agent ...
Die andere Häl e erhielt eine Standardbehandlung. Die beiden primä- ren Endpunkte waren ein Gewichtsverlust von mindestens 15 kg und eine Diabetes- Remission mit einem HbA1c-Wert unter 6,5% nach mindestens zwei Monaten ohne Antidiabetika. Innerhalb von zwölf Mo- naten hatten 24% der...
In den letzten Jahren wurden einige Mechanismen entdeckt, die neue potenzielle Angriffspunkte für die Therapie des Typ-2-Diabetes darstellen. Ziel der Forschung ist es auch, Behandlungsstrategien künftig noch besser an verschiedene Subtypen dieser chronischen Stoffwechselstörung anzupassen. This...
Behandlungsqualität von Patienten mit Diabetes mellitus Typ 1 und Typ 2 in Schwerpunktpraxis, Diabetesfachklinik und Akutkrankenhaus in der Bundesrepubl... INTRODUCTION: To improve diabetes care the German Diabetes Association created quality guidelines on two levels for certification of institutions...
Due to the confidence of overweight and obesity with type-2-diabetes mellitus and the dramatic increase of these diseases in the past years, the weight reduction is the main procedure to prevent these developments. Because diabetes mellitus causes a disease of the carbohydrate metabolism, the modera...
Use of a composition comprising an immunoglobulin, or a portion thereof, linked to a peptide, wherein the immunoglobulin or portion thereof is aggregated in the manufacture of a medicament for treating or preventing type 1 diabetes in subject in need thereof. Inventors...
Disclosed herein are methods for treating or preventing a disease in mammals having the characteristics of Type 1 diabetes comprising administering insulin or disease suppressive fragments of insulin or analogs thereof in oral or aerosol dosage forms to said mammals. Also disclosed herein are ...
Behandlung von typ ii diabetes mit dipeptidyl-peptidase-iv-hemmern Treatment of type ii diabetes with dipeptidyl peptidase-IV inhibitorsdoi:DE60215787 T2L Michel AUBERTFerring Research Institute Pierre BROQUADE
Insulin degludec (IDeg) is a new basal insulin, that has gained regulatory approval in Europe in January 2013 for the treatment of type 1 and type 2 diabetes. After subcutaneous injection, IDeg self-associates to form multihexamer chains that slowly dissociate into monomers. This results in a ...
Typ-1-Diabetes im asymptomatischen Frühstadium: Orales Insulin zur prventiven BehandlungAutoimmune diabetesImmunomodulationPrevention & controlAutoantigensChildBackground Insulin is usually the first target of the autoimmune response in children developing type 1 diabetes and is therefore considered a ...